Compare Sterling Biotech with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ALEMBIC LTD - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ALEMBIC LTD STERLING BIOTECH/
ALEMBIC LTD
 
P/E (TTM) x -0.4 69.6 - View Chart
P/BV x 0.0 2.5 0.6% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 STERLING BIOTECH   ALEMBIC LTD
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ALEMBIC LTD
Mar-18
STERLING BIOTECH/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1172 14.6%   
Low Rs334 10.0%   
Sales per share (Unadj.) Rs26.84.7 570.3%  
Earnings per share (Unadj.) Rs-15.06.1 -245.0%  
Cash flow per share (Unadj.) Rs-5.56.2 -87.5%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs54.940.7 135.0%  
Shares outstanding (eoy) m267.87267.03 100.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.311.3 2.3%   
Avg P/E ratio x-0.58.7 -5.4%  
P/CF ratio (eoy) x-1.38.5 -15.0%  
Price / Book Value ratio x0.11.3 9.7%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m1,86214,139 13.2%   
No. of employees `0001.4NA-   
Total wages/salary Rs m547207 263.6%   
Avg. sales/employee Rs Th5,303.3NM-  
Avg. wages/employee Rs Th403.8NM-  
Avg. net profit/employee Rs Th-2,959.0NM-  
INCOME DATA
Net Sales Rs m7,1811,255 572.1%  
Other income Rs m43370 11.5%   
Total revenues Rs m7,2231,625 444.4%   
Gross profit Rs m947111 852.3%  
Depreciation Rs m2,54338 6,728.0%   
Interest Rs m4,3772 257,476.5%   
Profit before tax Rs m-5,931442 -1,342.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,92424 -8,034.7%   
Profit after tax Rs m-4,0071,630 -245.8%  
Gross profit margin %13.28.9 149.0%  
Effective tax rate %32.45.4 598.5%   
Net profit margin %-55.8129.8 -43.0%  
BALANCE SHEET DATA
Current assets Rs m14,3351,867 767.8%   
Current liabilities Rs m49,809591 8,425.1%   
Net working cap to sales %-494.0101.6 -486.0%  
Current ratio x0.33.2 9.1%  
Inventory Days Days40394 428.0%  
Debtors Days Days17174 232.0%  
Net fixed assets Rs m55,4321,791 3,095.2%   
Share capital Rs m268534 50.2%   
"Free" reserves Rs m13,93510,324 135.0%   
Net worth Rs m14,70110,858 135.4%   
Long term debt Rs m9,47841 23,004.5%   
Total assets Rs m73,98811,591 638.4%  
Interest coverage x-0.4260.9 -0.1%   
Debt to equity ratio x0.60 16,990.1%  
Sales to assets ratio x0.10.1 89.6%   
Return on assets %0.514.1 3.6%  
Return on equity %-27.315.0 -181.6%  
Return on capital %-6.415.2 -42.3%  
Exports to sales %25.91.5 1,675.8%   
Imports to sales %0.221.0 0.8%   
Exports (fob) Rs m1,86019 9,586.6%   
Imports (cif) Rs m12263 4.6%   
Fx inflow Rs m1,86019 9,586.6%   
Fx outflow Rs m25264 9.4%   
Net fx Rs m1,835-244 -750.7%   
CASH FLOW
From Operations Rs m1,719236 728.9%  
From Investments Rs m-3,148-224 1,405.4%  
From Financial Activity Rs m1,426-27 -5,360.9%  
Net Cashflow Rs m-3-15 23.0%  

Share Holding

Indian Promoters % 33.9 64.0 53.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 9.9 9.7 102.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 26.1 150.6%  
Shareholders   21,482 54,701 39.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - SANOFI INDIA COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS